Paces Ferry Wealth Advisors LLC Acquires Shares of 4,843 Bristol-Myers Squibb (NYSE:BMY)

Paces Ferry Wealth Advisors LLC bought a new position in Bristol-Myers Squibb (NYSE:BMY - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,843 shares of the biopharmaceutical company's stock, valued at approximately $274,000.

Other hedge funds also recently modified their holdings of the company. Richwood Investment Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 6.5% during the 4th quarter. Richwood Investment Advisors LLC now owns 12,348 shares of the biopharmaceutical company's stock valued at $698,000 after acquiring an additional 750 shares during the last quarter. Heron Bay Capital Management grew its holdings in Bristol-Myers Squibb by 2.1% during the fourth quarter. Heron Bay Capital Management now owns 10,795 shares of the biopharmaceutical company's stock valued at $611,000 after purchasing an additional 220 shares during the last quarter. M Holdings Securities Inc. bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $39,000. Blueprint Investment Partners LLC lifted its stake in shares of Bristol-Myers Squibb by 51.0% in the fourth quarter. Blueprint Investment Partners LLC now owns 10,659 shares of the biopharmaceutical company's stock worth $603,000 after buying an additional 3,601 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth $817,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY traded down $0.31 on Thursday, hitting $58.90. The stock had a trading volume of 8,751,197 shares, compared to its average volume of 12,156,392. The firm's 50 day moving average price is $58.47 and its 200-day moving average price is $56.17. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a market capitalization of $119.52 billion, a price-to-earnings ratio of -13.33, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43.

Remove Ads

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, equities research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be given a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.21%. Bristol-Myers Squibb's payout ratio is -56.11%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BMY. Cantor Fitzgerald lifted their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Bank of America reiterated a "neutral" rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and increased their target price for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Finally, Truist Financial increased their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $57.86.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the acquisition, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.